Targeting the gatekeeper residue in phosphoinositide 3-kinases. Read more about Targeting the gatekeeper residue in phosphoinositide 3-kinases.
Development of alpha-keto-based inhibitors of cruzain, a cysteine protease implicated in Chagas disease. Read more about Development of alpha-keto-based inhibitors of cruzain, a cysteine protease implicated in Chagas disease.
The synthesis, distribution, and anti-hepatic cancer activity of YSL. Read more about The synthesis, distribution, and anti-hepatic cancer activity of YSL.
Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold. Read more about Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold.
Designed potent multivalent chemoattractants for Escherichia coli. Read more about Designed potent multivalent chemoattractants for Escherichia coli.
A molecular gate which controls unnatural ATP analogue recognition by the tyrosine kinase v-Src. Read more about A molecular gate which controls unnatural ATP analogue recognition by the tyrosine kinase v-Src.
Alkylation of a catalytic aspartate group of the SIV protease by an epoxide inhibitor. Read more about Alkylation of a catalytic aspartate group of the SIV protease by an epoxide inhibitor.
Synthesis, pharmacology, and molecular modeling of novel 4-alkyloxy indole derivatives related to cannabimimetic aminoalkyl indoles (AAIs). Read more about Synthesis, pharmacology, and molecular modeling of novel 4-alkyloxy indole derivatives related to cannabimimetic aminoalkyl indoles (AAIs).
The discovery, characterization and crystallographically determined binding mode of an FMOC-containing inhibitor of HIV-1 protease. Read more about The discovery, characterization and crystallographically determined binding mode of an FMOC-containing inhibitor of HIV-1 protease.
Structure-based design of parasitic protease inhibitors. Read more about Structure-based design of parasitic protease inhibitors.
